Andreas Halvorsen acquired 1.11 Million Immunovant shares worth $18.3 Million. That's 0.05% of their equity portfolio (76th largest holding). Andreas Halvorsen started to build up the position in Immunovant in Q1 2024 and continued to invest until Q2 2024. Since then they sold 1.21 Million shares. The investor's estimated purchase price is $38.7 Million, resulting in a loss of 53%.